Dual Anti-HER2 Tx Shows Benefit in Advanced CRC

(MedPage Today) -- Strategy yielded a 40% response rate in KRAS wild-type, HER2-amplified disease
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Gastroenterology | HER2